Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 860405, 11 pages
http://dx.doi.org/10.1155/2015/860405
Research Article

Variants of SCARB1 and VDR Involved in Complex Genetic Interactions May Be Implicated in the Genetic Susceptibility to Clear Cell Renal Cell Carcinoma

1Institute of Zoology, Faculty of Biology and Earth Sciences, Jagiellonian University, Gronostajowa 9, 30-387 Cracow, Poland
2Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Cracow, Poland
3Centre of Oncology, Maria Skłodowska-Curie Memorial Institute, Garncarska 11, 31-115 Cracow, Poland
4Department of Dermatology, Collegium Medicum of the Jagiellonian University, Skawińska 8, 31-066 Cracow, Poland

Received 8 October 2014; Revised 21 February 2015; Accepted 15 March 2015

Academic Editor: Zhaoming Wang

Copyright © 2015 Ewelina Pośpiech et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Storkel, J. N. Eble, K. Adlakha et al., “Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC),” Cancer, vol. 80, no. 5, pp. 987–989, 1997. View at Google Scholar
  2. E. Maubec, V. Chaudru, H. Mohamdi et al., “Characteristics of the coexistence of melanoma and renal cell carcinoma,” Cancer, vol. 116, no. 24, pp. 5716–5724, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. C. Yu, T. M. Mack, R. Hanisch, C. Cicioni, and B. E. Henderson, “Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma,” Journal of the National Cancer Institute, vol. 77, no. 2, pp. 351–356, 1986. View at Google Scholar · View at Scopus
  4. W.-H. Chow, G. Gridley, J. F. Fraumeni, and B. Järvholm, “Obesity, hypertension, and the risk of kidney cancer in men,” The New England Journal of Medicine, vol. 343, no. 18, pp. 1305–1311, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al., “Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012,” European Journal of Cancer, vol. 49, no. 6, pp. 1374–1403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. P. Purdue, M. Johansson, D. Zelenika et al., “Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3,” Nature Genetics, vol. 43, no. 1, pp. 60–65, 2011. View at Google Scholar
  7. J. P. T. Higgins, R. Shinghal, H. Gill et al., “Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray,” The American Journal of Pathology, vol. 162, no. 3, pp. 925–932, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. S. S. Han, M. Yeager, L. E. Moore et al., “The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma,” Human Molecular Genetics, vol. 21, no. 5, pp. 1190–1200, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Wu, G. Scelo, M. P. Purdue et al., “A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23,” Human Molecular Genetics, vol. 21, no. 2, pp. 456–462, 2012. View at Google Scholar
  10. M. Henrion, M. Frampton, G. Scelo et al., “Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer,” Human Molecular Genetics, vol. 22, no. 4, pp. 825–831, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. P. Purdue, Y. Ye, Z. Wang et al., “A genome-wide association study of renal cell carcinoma among African Americans,” Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 1, pp. 209–214, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. U. H. Frey, G. Lümmen, T. Jäger et al., “The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma,” Clinical Cancer Research, vol. 12, no. 3, pp. 759–763, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Karami, P. Brennan, P. S. Rosenberg et al., “Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk,” PLoS ONE, vol. 4, no. 9, Article ID e7013, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Bruyère, C. M. Hovens, M.-N. Marson et al., “VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma,” The Journal of Urology, vol. 184, no. 4, pp. 1273–1278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Qin, Q. Cao, P. Li et al., “Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population,” PLoS ONE, vol. 7, no. 1, Article ID e28829, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Wang, X. Pan, X. Huo et al., “A functional polymorphism C-1310G in the promoter region of Ku70/XRCC6 is associated with risk of renal cell carcinoma,” Molecular Carcinogenesis, vol. 51, supplement 1, pp. E183–E190, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. De Martino, A. Haitel, G. Schatzl, H. C. Klingler, and T. Klatte, “The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis,” The Journal of Urology, vol. 190, no. 2, pp. 717–722, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Matsushita, O. Takeuchi, D. M. Standley et al., “Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay,” Nature, vol. 458, no. 7242, pp. 1185–1190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Mizgalska, P. Wgrzyn, K. Murzyn et al., “Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1β mRNA,” The FEBS Journal, vol. 276, no. 24, pp. 7386–7399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Skalniak, D. Mizgalska, A. Zarebski, P. Wyrzykowska, A. Koj, and J. Jura, “Regulatory feedback loop between NF-κB and MCP-1-induced protein 1 RNase,” The FEBS Journal, vol. 276, no. 20, pp. 5892–5905, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Liang, Y. Saad, T. Lei et al., “MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling,” Journal of Experimental Medicine, vol. 207, no. 13, pp. 2959–2973, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Pośpiech, J. Draus-Barini, T. Kupiec, A. Wojas-Pelc, and W. Branicki, “Gene-gene interactions contribute to eye colour variation in humans,” Journal of Human Genetics, vol. 56, no. 6, pp. 447–455, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Pośpiech, A. Wojas-Pelc, S. Walsh et al., “The common occurrence of epistasis in the determination of human pigmentation and its impact on DNA-based pigmentation phenotype prediction,” Forensic Science International: Genetics, vol. 11, no. 1, pp. 64–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Healy, S. A. Jordan, P. S. Budd, R. Suffolk, J. L. Rees, and I. J. Jackson, “Functional variation of MC1R alleles from red-haired individuals,” Human Molecular Genetics, vol. 10, no. 21, pp. 2397–2402, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Nejentsev, L. Godfrey, H. Snook et al., “Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene,” Human Molecular Genetics, vol. 13, no. 15, pp. 1633–1639, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Dempfle, S. A. Wudy, K. Saar et al., “Evidence for involvement of the vitamin D receptor gene in idiopathic short stature via a genome-wide linkage study and subsequent association studies,” Human Molecular Genetics, vol. 15, no. 18, pp. 2772–2783, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. R. A. Sturm, D. L. Duffy, N. F. Box et al., “The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes,” Pigment Cell Research, vol. 16, no. 3, pp. 266–272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. D. Ritchie, L. W. Hahn, N. Roodi et al., “Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer,” The American Journal of Human Genetics, vol. 69, no. 1, pp. 138–147, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Jakulin and I. Bratko, “Analyzing attribute dependencies,” in Knowledge Discovery in Databases: PKDD 2003, vol. 2838 of Lecture Notes in Computer Science, pp. 229–240, 2003. View at Publisher · View at Google Scholar
  30. E. Kontopantelis and D. Reeves, “MetaEasy: a meta-analysis add-in for Microsoft Excel,” Journal of Statistical Software, vol. 30, no. 7, pp. 1–25, 2009. View at Google Scholar
  31. D. G. Altman and J. M. Bland, “How to obtain the confidence interval from a P value,” British Medical Journal, vol. 343, Article ID d2090, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. D. L. Williams, R. E. Temel, and M. A. Connelly, “Roles of scavenger receptor BI and apo A-I in selective uptake of HDL cholesterol by adrenal cells,” Endocrine Research, vol. 26, no. 4, pp. 639–651, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. W.-J. Shen, J. Hu, Z. Hu, F. B. Kraemer, and S. Azhar, “Scavenger receptor class B type I (SR-BI): a versatile receptor with multiple functions and actions,” Metabolism: Clinical and Experimental, vol. 63, no. 7, pp. 875–886, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Danilo, J. L. Gutierrez-Pajares, M. A. Mainieri, I. Mercier, M. P. Lisanti, and P. G. Frank, “Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development,” Breast Cancer Research, vol. 15, no. 5, article R87, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Cao, C. Qin, X. Ju et al., “Chromosome 11q13.3 variant modifies renal cell cancer risk in a Chinese population,” Mutagenesis, vol. 27, no. 3, pp. 345–350, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Su, Y. Han, Y. Yu et al., “A GWAS-identified susceptibility locus on chromosome 11q13.3 and its putative molecular target for prediction of postoperative prognosis of human renal cell carcinoma,” Oncology Letters, vol. 6, no. 2, pp. 421–426, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Colston, M. J. Colston, and D. Feldman, “1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture,” Endocrinology, vol. 108, no. 3, pp. 1083–1088, 1981. View at Publisher · View at Google Scholar · View at Scopus
  38. S. R. T. Evans, A. M. Houghton, L. Schumaker et al., “Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines,” The Journal of Surgical Research, vol. 61, no. 1, pp. 127–133, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Okamoto, T. Fujioka, and S. Horiuchi, “A study of the metabolism of vitamin D in patients with renal cell carcinoma. With special reference to serum concentration of 1α, 25-(OH)2D and its clinicla significance,” The Japanese Journal of Urology, vol. 82, no. 6, pp. 890–899, 1991. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Fujioka, Y. Suzuki, T. Okamoto, N. Mastushita, M. Hasegawa, and S. Omori, “Prevention of renal cell carcinoma by active vitamin D3,” World Journal of Surgery, vol. 24, no. 10, pp. 1205–1210, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Carlberg, S. Seuter, and S. Heikkinen, “The first genome-wide view of vitamin D receptor locations and their mechanistic implications,” Anticancer Research, vol. 32, no. 1, pp. 271–282, 2012. View at Google Scholar · View at Scopus
  42. K. Köstner, N. Denzer, C. S. L. Müller, R. Klein, W. Tilgen, and J. Reichrath, “The relevance of vitamin D Receptor (VDR) gene polymorphisms for cancer: a review of the literature,” Anticancer Research, vol. 29, no. 9, pp. 3511–3536, 2009. View at Google Scholar · View at Scopus
  43. D. Bretherton-Watt, R. Given-Wilson, J. L. Mansi, V. Thomas, N. Carter, and K. W. Colston, “Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population,” British Journal of Cancer, vol. 85, no. 2, pp. 171–175, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. H. S. Kim, P. A. Newcomb, C. M. Ulrich et al., “Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 8, pp. 869–874, 2001. View at Google Scholar · View at Scopus
  45. G. Lurie, L. R. Wilkens, P. J. Thompson et al., “Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 12, pp. 2566–2571, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Kosiniak-Kamysz, A. Marczakiewicz-Lustig, M. Marcińska et al., “Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects,” Melanoma Research, vol. 24, no. 4, pp. 388–396, 2014. View at Publisher · View at Google Scholar
  47. B. Toptaş, A. M. Kafadar, C. Cacina et al., “The vitamin D receptor (VDR) gene polymorphisms in Turkish brain cancer patients,” BioMed Research International, vol. 2013, Article ID 295791, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. I. Khan, Z. F. Bielecka, M. Z. Najm et al., “Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (Review),” International Journal of Oncology, vol. 44, no. 2, pp. 349–363, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Gandini, P. Gnagnarella, D. Serrano et al., “Vitamin D receptor polymorphisms and cancer,” Advances in Experimental Medicine and Biology, vol. 810, pp. 69–105, 2014. View at Google Scholar
  50. T. Ikuyama, T. Hamasaki, H. Inatomi, T. Katoh, T. Muratani, and T. Matsumoto, “Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese,” Endocrine Journal, vol. 49, no. 4, pp. 433–438, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. W. Obara, Y. Suzuki, K. Kato, S. Tanji, R. Konda, and T. Fujioka, “Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population,” International Journal of Urology, vol. 14, no. 6, pp. 483–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Ou, H. L. Zhao, B. Zhu, L. S. Huang, P. Z. Li, and M. Lao, “Association of vitamin D receptor gene polymorphism with the risk of renal cell carcinoma: a meta-analysis,” Journal of Receptors and Signal Transduction, vol. 34, no. 6, pp. 463–468, 2014. View at Publisher · View at Google Scholar
  53. F. Meng, P. Ma, C. Sui et al., “The association between VDR polymorphisms and renal cell carcinoma susceptibility: a meta-analysis,” Tumor Biology, vol. 35, no. 6, pp. 6065–6072, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. N. A. Morrison, J. C. Qi, A. Tokita et al., “Prediction of bone density from vitamin D receptor alleles,” Nature, vol. 20, no. 367, pp. 284–287, 1994. View at Google Scholar · View at Scopus
  55. R. Moonesinghe, M. J. Khoury, T. Liu, and J. P. A. Ioannidis, “Required sample size and nonreplicability thresholds for heterogeneous genetic associations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 2, pp. 617–622, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. Moore, “The ubiquitous nature of epistasis in determining susceptibility to common human diseases,” Human Heredity, vol. 56, no. 1–3, pp. 73–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. L. W. Hahn, M. D. Ritchie, and J. H. Moore, “Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions,” Bioinformatics, vol. 19, no. 3, pp. 376–382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Lania and A. Spada, “G-protein and signalling in pituitary tumours,” Hormone Research, vol. 71, supplement 2, pp. 95–100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. U. H. Frey, A. Eisenhardt, G. Lümmen et al., “The T393C polymorphism of the Gαs gene (GNAS1) is a novel prognostic marker in bladder cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 4, pp. 871–877, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. W. Arjumand, S. T. Ahmad, S. Nafees et al., “GNAS1 (Gαs) gene T393C polymorphism and renal cell carcinoma risk in a north Indian population: a case-control study,” Genetic Testing and Molecular Biomarkers, vol. 16, no. 9, pp. 1062–1066, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Kapellos, K. Polonifi, D. Farmakis et al., “Overexpression of Survivin levels in circulation and tissue samples of lung cancer patients,” Anticancer Research, vol. 33, no. 8, pp. 3475–3480, 2013. View at Google Scholar · View at Scopus
  62. J. Song, H. Su, Y.-Y. Zhou, and L.-L. Guo, “Prognostic value of survivin expression in breast cancer patients: a meta-analysis,” Tumor Biology, vol. 34, no. 4, pp. 2053–2062, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Lei, Z. Geng, W. Guo-Jun, W. He, and Y. Jian-Lin, “Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance,” Molecular and Cellular Biochemistry, vol. 344, no. 1-2, pp. 23–31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. J. S. Jang, K. M. Kim, K. H. Kang et al., “Polymorphisms in the survivin gene and the risk of lung cancer,” Lung Cancer, vol. 60, no. 1, pp. 31–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. A. M. F. Liu, R. K. H. Lo, C. S. S. Wong, C. Morris, H. Wise, and Y. H. Wong, “Activation of STAT3 by Gαs distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase,” The Journal of Biological Chemistry, vol. 281, no. 47, pp. 35812–35825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Aoki, G. M. Feldman, and G. Tosato, “Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma,” Blood, vol. 101, no. 4, pp. 1535–1542, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. W. Yang, K. Yoshigoe, X. Qin et al., “Identification of genes and pathways involved in kidney renal clear cell carcinoma,” BMC Bioinformatics, vol. 15, supplement 17, article S2, 2014. View at Publisher · View at Google Scholar
  68. S.-I. Miura, M. Fujino, Y. Matsuo et al., “High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 802–808, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Zamanian-Daryoush, D. Lindner, T. C. Tallant et al., “The cardioprotective protein apolipoprotein a1 promotes potent anti-tumorigenic effects,” The Journal of Biological Chemistry, vol. 288, no. 29, pp. 21237–21252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. V. H. Haase, “The VHL tumor suppressor: master regulator of HIF,” Current Pharmaceutical Design, vol. 15, no. 33, pp. 3895–3903, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. X. Na, H. O. Duan, E. M. Messing et al., “Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein,” The EMBO Journal, vol. 22, no. 16, pp. 4249–4259, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. B. I. Rini and E. J. Small, “Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 1028–1043, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. U. Brudnik, W. Branicki, A. Wojas-Pelc, and P. Kanas, “The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population,” Experimental Dermatology, vol. 18, no. 2, pp. 167–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. D. L. Duffy, Z. Z. Zhao, R. A. Sturm, N. K. Hayward, N. G. Martin, and G. W. Montgomery, “Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma,” The Journal of Investigative Dermatology, vol. 130, no. 2, pp. 520–528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Beisland, O. Talleraas, A. Bakke, and J. Norstein, “Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study,” BJU International, vol. 97, no. 4, pp. 698–702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. P. T. Bradford, D. M. Freedman, A. M. Goldstein, and M. A. Tucker, “Increased risk of second primary cancers after a diagnosis of melanoma,” Archives of Dermatology, vol. 146, no. 3, pp. 265–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Bertolotto, F. Lesueur, S. Giuliano et al., “A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma,” Nature, vol. 480, no. 7375, pp. 94–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Lindskog, K. Ebefors, M. E. Johansson et al., “Melanocortin 1 receptor agonists reduce proteinuria,” Journal of the American Society of Nephrology, vol. 21, no. 8, pp. 1290–1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. Z. Hochberg and A. R. Templeton, “Evolutionary perspective in skin color, vitamin D and its receptor,” Hormones, vol. 9, no. 4, pp. 307–311, 2010. View at Publisher · View at Google Scholar · View at Scopus